N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS
申请人:BABIN Didier
公开号:US20100093668A1
公开(公告)日:2010-04-15
The disclosure relates to a compound of formula (I):
wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.
Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
申请人:ZENECA LIMITED
公开号:US20030207882A1
公开(公告)日:2003-11-06
Compounds of formula (I), wherein G
1
is CH or N; G
2
is CH or N; R
1
is a variety of optional substituents, L
1
is (1-4C)alkylene; T
1
is CH or N; R
2
and R
3
are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X
1
and X
2
represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described.
1
AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS
申请人:AstraZeneca AB
公开号:EP0880502B1
公开(公告)日:2004-09-01
DERIVES DE N, N' - 2, 4 -DIANILINO PYRIMIDINES, LEUR UTILISATION COMME INHIBITEURS DE IKK, LEUR PREPARATION ET LEUR COMPOSITIONS PHARMACEUTIQUES
申请人:Sanofi-Aventis
公开号:EP2118092A1
公开(公告)日:2009-11-18
[EN] AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS<br/>[FR] DERIVES AMINOHETEROCYCLIQUES EN TANT QU'AGENTS ANTI-THROMBOTIQUES OU ANTICOAGULANTS
申请人:ZENECA LIMITED
公开号:WO1997028129A1
公开(公告)日:1997-08-07
(EN) Compounds of formula (I), wherein G1 is CH or N; G2 is CH or N; R1 is a variety of optional substituents; L1 is (1-4C)alkylene; T1 is CH or N; R2 and R3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X1 and X2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described.(FR) Composés représentés par la formule (I): dans laquelle G1 représente CH ou N; G2 représente CH ou N; R1 représente une variété de substituants éventuels; L1 représente alkylène C1-4; T1 représente CH ou N; R2 et R3 représentent indépendamment hydrogène ou alkyle C1-4 ou sont réunis afin de constituer un noyau; X1 et X2 représentent différents groupes de liaison; Ar représente phénylène ou certains noyaux hétéroaryle et Q représente une variété de systèmes de noyaux aromatiques ou hétérocycliques, ainsi que leurs sels acceptables sur le plan pharmacologique. Ces composés sont utiles en tant qu'agents anti-thrombotiques et anticoagulants et sont des inhibiteurs sélectifs du Facteur Xa. On décrit également des procédés servant à les préparer et des compositions pharmaceutiques les contenant.